DSP Healthcare Fund
An open ended equity scheme investing in healthcare and pharmaceutical sector
DSP Healthcare Fund
An open ended equity scheme investing in healthcare and pharmaceutical sector

Fund Manager

Vinit Sambre
Total work experience of 21 years.
Managing this Scheme since November 2018.

Jay Kothari (Dedicated Fund Manager for overseas investments)
Total work experience of 16 years.
Managing this Scheme since November 2018.

Inception date

Nov 30, 2018

Benchmark

S&P BSE HEALTHCARE (TRI)

NAV
Regular Plan  
Growth: ₹ 18.239
Direct Plan  
Growth: ₹ 18.884
Total aum

₹ 956 Cr

Monthly average aum

₹ 920 Cr

Portfolio Turnover Ratio(Last 12 months):

0.20

Month End Expense Ratio
Regular Plan : 2.30%
Direct Plan : 0.78%
Fund Category

Sectoral\Thematic

Tenure

2 Yr

Exit Load

Holding period <12 months: 1%
Holding period >=12 months: Nil

Data As On November 27, 2020

Name of Instrument% to Net Assets
EQUITY & EQUITY RELATED
Listed / awaiting listing on the stock exchanges
Pharmaceuticals 64.46
✔ Cipla Limited 9.20
✔ IPCA Laboratories Limited 8.94
✔ Dr. Reddy's Laboratories Limited 8.45
✔ Divi's Laboratories Limited 6.34
✔ Procter & Gamble Health Limited 6.12
✔ Torrent Pharmaceuticals Limited 3.88
JB Chemicals & Pharmaceuticals Limited 3.28
Syngene International Limited 2.81
Alkem Laboratories Limited 2.59
Jubilant Life Sciences Limited 2.33
Alembic Pharmaceuticals Limited 2.32
Aarti Drugs Limited 2.28
Indoco Remedies Limited 2.27
Unichem Laboratories Limited 1.75
Abbott India Limited 1.02
Ajanta Pharma Limited 0.87
Healthcare Services 14.47
✔ Apollo Hospitals Enterprise Limited 5.17
✔ Max Healthcare Institute Limited 3.55
Dr. Lal Path Labs Ltd. 3.09
Narayana Hrudayalaya Ltd. 2.66
Finance 3.66
✔ ICICI Lombard General Insurance Company Limited 3.66
Total 82.58
Foreign Securities and/or overseas ETF(s)
Listed / awaiting listing on the stock exchanges
Pharmaceuticals 6.15
✔ Intuitive Surgical Inc 3.52
Abbott Laboratories 2.62
Healthcare Services 2.81
Abiomed Inc 2.81
Total 8.95
MONEY MARKET INSTRUMENTS
TREPS / Reverse Repo Investments / Corporate Debt Repo 8.26
Total 8.26
Cash & Cash Equivalent
Net Receivables/Payables 0.21
Total 0.21
GRAND TOTAL 100.00

as on 27th Nov'20

✔ Top Ten Holdings


Growth of Rs. 1 L invested at inception: 1.82 L

SIP Returns(In %)
SI*
51.61
*SI - Since inception
Outperformed Benchmark TRI (calendar year) S&P BSE HEALTHCARE (TRI)
9%

Rolling Return
  1 yr
Minimum (%)-5.7
Maximum (%)85.7
Average (%)38.0
% times negative returns2.0
% of times returns are in
excess of 7%		90.0
Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns are for Regular Plan - Growth Option Click here for performance in SEBI prescribed format.

Large Cap: 1st -100th company in terms of full market capitalization
Mid Cap: 101st -250th company in terms of full market capitalization
Small Cap: 251st company onwards in terms of full market capitalization.

 
Positions Increased
Pharmaceuticals
Procter & Gamble Health Limited
IPCA Laboratories Limited
Cipla Limited
 
Positions Decreased
Pharmaceuticals
JB Chemicals & Pharmaceuticals Limited
Aarti Drugs Limited
Note: The above position change is compared to last month-end data.
Rebalances below 0.25 % are not considered.

Investment Objective

The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
However, there can be no assurance that the investment objective of the scheme will be realized.

Product Labelling

This open ended equity Scheme is suitable for investors who are seeking*
• Long term capital growth
• Investment in equity and equity related Securities of healthcare and pharmaceutical companies

* Investors should consult their financial advisors if in doubt whether the product is suitable for them.